Incyte Corporation (INCY) — Fair Value Analysis

Base-case fair value (P50): $94.65 · Current price: $95.31 · Verdict: Fairly Valued

The Verdict on INCY

Based on our Monte Carlo simulations, Incyte (INCY) is currently assessed as Fairly Valued. At a current price of $99.31, INCY trades marginally above its median fair value (P50) of $95.69, representing a narrow -3.6% gap. This slight premium suggests that the market price closely aligns with the fundamental valuation derived from thousands of forward-looking scenarios, indicating that the stock is neither significantly overvalued nor undervalued at this time.

How INCY stacks up against Healthcare

Incyte's operational and financial health is categorized as "average" within the Healthcare sector. This "average" quality tier implies that while INCY maintains a stable business, its overall profile does not present a substantial premium or discount relative to its peers. The current price of $99.31 reflects a valuation consistent with a company in this quality bracket, where its fundamental fair value of $95.69 indicates limited immediate upside or downside from a pure valuation perspective, based on its sector standing and current market price.

What this means for investors

The "Fairly Valued" verdict for INCY, with its current price of $99.31 hovering just -3.6% above its P50 fair value of $95.69, suggests that investors are not currently paying a significant premium. While this narrow gap might limit immediate valuation-driven gains, it also mitigates substantial downside risk based purely on fundamental overvaluation. Our Monte Carlo simulations also produce a distribution of potential outcomes, including both a downside scenario and a bull case, which are crucial for a comprehensive risk-reward assessment. Sign up for FairCurve to see the full bear and bull distribution and track INCY's fair value as new fundamentals are released.